0.4889
1.88%
+0.009
After Hours:
.4889
Centogene NV stock is currently priced at $0.4889, with a 24-hour trading volume of 6,941.
It has seen a +1.88% increased in the last 24 hours and a -29.14% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.4669 pivot point. If it approaches the $0.4929 resistance level, significant changes may occur.
Previous Close:
$0.4799
Open:
$0.4899
24h Volume:
6,941
Market Cap:
$13.62M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-0.3601
EPS:
-1.3577
Net Cash Flow:
-
1W Performance:
+7.24%
1M Performance:
-29.14%
6M Performance:
-53.60%
1Y Performance:
-64.83%
Centogene NV Stock (CNTG) Company Profile
Name
Centogene NV
Sector
Industry
Phone
49 381 80113 500
Address
Am Strande 7, Rostock
Centogene NV Stock (CNTG) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Apr-24-20 | Downgrade | Evercore ISI | Outperform → In-line |
Dec-03-19 | Initiated | Robert W. Baird | Outperform |
Dec-02-19 | Initiated | BTIG Research | Buy |
Dec-02-19 | Initiated | Evercore ISI | Outperform |
Centogene NV Stock (CNTG) Latest News
CENTOGENE Receives Nasdaq Non-Compliance Notice
GlobeNewswire Inc.
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
GlobeNewswire Inc.
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
GlobeNewswire Inc.
CENTOGENE Explores Strategic Alternatives
GlobeNewswire Inc.
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
GlobeNewswire Inc.
CENTOGENE Receives French Research Tax Credit Accreditation
GlobeNewswire Inc.
Centogene NV Stock (CNTG) Financials Data
There is no financial data for Centogene NV (CNTG). Check out other stocks for more information.
About Centogene NV
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Cap:
|
Volume (24h):